On March 31, 2021 mAbxience reported The European Commission (EC) has approved its MB02 biosimilar to Avastin (Bevacizumab), in Europe (Press release, mAbxience, MAR 31, 2021, View Source [SID1234577412]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MB02, to be commercialized as Alymsys and Oyavas, is highly similar to the reference medicinal product and data has shown a comparable quality, safety and efficacy to Avastin. MB02 is intended for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

"We are currently witnessing a period of vital importance globally, with a key focus on the healthcare system and its sustainability" said Emmanuelle Lepine, General Manager at mAbxience.
"The launch of our Bevacizumab under the trademarks Alymsys and Oyavas in the European market will be a perfect example of how innovation and cutting-edge R&D technology can be applied to obtain a high quality, affordable medicine which, as well as providing alternatives for the healthcare system, will also improve patient access to costly treatments."